First Horizon Corp Blueprint Medicines Corp Transaction History

First Horizon Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 24, 2025	SELL	$128.2 - $129.46 $9,743 - $9,838	-76 Closed	0 $0
Q1 2021 May 11, 2021	SELL	$90.71 - $108.28 $181 - $216	-2 Reduced 2.56%	76 $7,000
Q4 2020 Feb 11, 2021	SELL	$92.08 - $124.48 $1,104 - $1,493	-12 Reduced 13.33%	78 $8,000
Q3 2020 Nov 12, 2020	BUY	$66.45 - $92.7 $5,980 - $8,343	90 New	90 $8,000

367

66.9M

973K

1.54M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $7.73B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of First Horizon Corp, based on Form 13F filings with the SEC.

Stay updated on First Horizon Corp with notifications on news.